Northwest Biotherapeutics (NWBO) Amortizatization of Intangibles (2010 - 2026)
Northwest Biotherapeutics (NWBO) posted quarterly Amortizatization of Intangibles of $358000.0 for Q4 2017, up 69.67% year-over-year from $211000.0 in Q4 2016, and up 3.77% quarter-over-quarter from $345000.0 in Q3 2017.
Powered by 
Analysis
Northwest Biotherapeutics (NWBO) Amortizatization of Intangibles (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Amortizatization of Intangibles history runs 8 years deep, the most recent figure standing at $358000.0 for Q4 2017.
- In Q4 2017, Amortizatization of Intangibles rose 69.67% year-over-year to $358000.0; the TTM figure through Dec 2017 stood at $1.3 million (up 201.43% YoY), while the FY2020 annual figure was $122000.0, up 320.69% from the prior year.
- Amortizatization of Intangibles for Q4 2017 stood at $358000.0, up from $345000.0 in the prior quarter.
- The five-year high for Amortizatization of Intangibles was $373000.0 in Q1 2017, with the low at -$71000.0 in Q4 2014.
- The 5-year median for Amortizatization of Intangibles is $190000.0 (2017), against an average of $174923.1.
- Peak annual rise in Amortizatization of Intangibles reached 373.33% in 2014, while the deepest fall reached 308.82% in 2014.
- Northwest Biotherapeutics' Amortizatization of Intangibles stood at $34000.0 in 2013, then tumbled by 308.82% to -$71000.0 in 2014, then soared by 180.28% to $57000.0 in 2015, then surged by 270.18% to $211000.0 in 2016, then surged by 69.67% to $358000.0 in 2017.
- Business Quant data shows NWBO's Amortizatization of Intangibles at $358000.0 in Q4 2017, $345000.0 in Q3 2017, and $190000.0 in Q2 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Northwest Biotherapeutics | 278.23 Mn | 277.63 Mn | - | 78,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 78,000.00 |
| Mar 31, 2026 | 76,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | 70,000.00 |
| Jun 30, 2025 | 66,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 82,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Sep 30, 2023 | 73,000.00 |
| Jun 30, 2023 | 71,000.00 |
| Mar 31, 2023 | 67,000.00 |
| Sep 30, 2022 | 63,000.00 |
| Dec 31, 2017 | 358,000.00 |
| Sep 30, 2017 | 345,000.00 |
| Jun 30, 2017 | 190,000.00 |
| Mar 31, 2017 | 373,000.00 |
| Dec 31, 2016 | 211,000.00 |
| Mar 31, 2016 | 209,000.00 |